Moderna beat estimates, raised its 2026 sales forecast, and expects more cash at year-end. The failed norovirus trial is a setback, but stronger sales, lower research costs, and cancer-trial progress leave the company better positioned.
Stronger international vaccine sales and lower research costs supported the results. The failed norovirus trial is a setback, but the raised forecast, larger cash balance, and positive cancer-trial data carry more weight.
The cancer treatment used with Merck's Keytruda reduced melanoma recurrence or death risk. The story reports no approval or sales result, but the trial finding supports Merck's cancer-treatment work.
Follow Moderna Inc. (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRNA